USA flag logo/image

An Official Website of the United States Government

VEGF-driven PET imaging of tumor angiogenesis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85597
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
EB006679
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
SIBTECH, INC.
115A Commerce Drive Brookfield, CT 06804-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: VEGF-driven PET imaging of tumor angiogenesis
Agency: HHS
Contract: 1R43EB006679-01A2
Award Amount: $182,582.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall goal of this project is development of targeted PET probes for molecular imaging of receptors for vascular endothelial growth factor (VEGF), a crucial drug target in oncology patients. Tumor imaging with FDG , as well as imaging of tumor vasculature with blood pool contrast agents, provides important general information on tumor size and metabolic activity of tumor cells. However, molecular imaging of specific drug targets would greatly facilitate development of new drugs, rational selection of patients, and development of personalized treatment regiments. In our original submission on 12/01/2005 and the first resubmission on 04/01/2006 we proposed to synthesize and test in vivoa VEGF-based Cu PET radiotracer f or imaging 64 VEGF receptors in tumor vasculature. By now, our lead radiotracer, named scVEGF/Cu, has been developed and validated in mouse tumor models. scVEGF/Cu selectively and specifically image VEGF receptors in tumor vasculature. In contrast, either functionally inactivated or blocked scVEGF/Cu display only negligible accumulation in tumor. scVEGF/Cu provides excellent PET images, displays unusually low non-specific organ uptake, essentially does not degrade or dissociate through the clearance time, a nd lacks detectable tumor-stimulating effects. Finally, a fluorescent scVEGF-based probe colocalizes with endothelial cell markers in vivo. In view of these results, we can now proceed with validation of scVEGF/Cu for a potential clinical use. Since the go al of molecular PET imaging of VEGF receptors is to characterize their prevalence in individual patients, it is now necessary to establish how imaging with scVEGF/Cu is linked to VEGF receptor prevalence and what roles play endogenous tumor VEGF and tumor perfusion in uptake of radiotracer. We propose an integrated experimental approach to answer these questions that are crucial for understanding how scVEGF/Cu radiotracer can be used in individual patients for characterizing of VEGF receptor prevalence. Acc omplishing Specific Aims of this proposal will provide a rational basis for GMP-production, formal toxicology and initial clinical trials in Phase II of this project.

Principal Investigator:

Joseph M. Backer
2037755677
JBACKER@SIBTECH.COM

Business Contact:

Joseph M. Backer
jbacker@sibtech.com
Small Business Information at Submission:

SIBTECH, INC.
115A Commerce Drive Brookfield, CT 06804

EIN/Tax ID: 133992292
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No